Grifols (NASDAQ:GRFS) Posts Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Grifols (NASDAQ:GRFS) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21), reports. The company had revenue of $1.96 billion for the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. Grifols updated its FY 2024 guidance to EPS.

Grifols Stock Up 2.3 %

Shares of NASDAQ GRFS opened at $7.64 on Friday. The firm has a 50 day moving average of $7.39 and a 200 day moving average of $7.27. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79. Grifols has a 12-month low of $5.30 and a 12-month high of $12.15.

Institutional Trading of Grifols

Several large investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. grew its position in Grifols by 5.9% during the fourth quarter. QRG Capital Management Inc. now owns 35,116 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 1,964 shares during the period. Team Hewins LLC grew its position in Grifols by 11.8% during the first quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 4,324 shares during the period. Capital Group Investment Management PTE. LTD. grew its position in Grifols by 11.8% during the first quarter. Capital Group Investment Management PTE. LTD. now owns 81,955 shares of the biotechnology company’s stock valued at $547,000 after buying an additional 8,660 shares during the period. Cardinal Capital Management boosted its position in shares of Grifols by 10.4% in the fourth quarter. Cardinal Capital Management now owns 93,616 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 8,789 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Grifols by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 9,350 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.